300636 同和药业
午间休市 12-19 11:30:00
资讯
新帖
简况
同和药业:公司仅在定期报告中披露截至报告期末的股东人数
证券日报 · 12-05
同和药业:公司仅在定期报告中披露截至报告期末的股东人数
同和药业:新产能扩建已有潜在客户
证券之星 · 12-02
同和药业:新产能扩建已有潜在客户
同和药业(300636)披露2025年第一次临时股东大会决议公告,11月12日股价上涨0.36%
证券之星 · 11-12
同和药业(300636)披露2025年第一次临时股东大会决议公告,11月12日股价上涨0.36%
同和药业(300636.SZ)通过美国FDA现场检查
智通财经 · 11-03
同和药业(300636.SZ)通过美国FDA现场检查
股市必读:同和药业(300636)股东户数1.55万户,较上期减少3.02%
证券之星 · 10-27
股市必读:同和药业(300636)股东户数1.55万户,较上期减少3.02%
同和药业(300636)披露召开2025年第一次临时股东大会通知,10月24日股价上涨1.62%
证券之星 · 10-24
同和药业(300636)披露召开2025年第一次临时股东大会通知,10月24日股价上涨1.62%
同和药业(300636.SZ)获得欧洲药典适应性证书
智通财经 · 09-16
同和药业(300636.SZ)获得欧洲药典适应性证书
【机构调研记录】湘财基金调研同和药业、分众传媒等3只个股(附名单)
证券之星 · 09-02
【机构调研记录】湘财基金调研同和药业、分众传媒等3只个股(附名单)
股市必读:同和药业中报 - 第二季度单季净利润同比增长45.08%
证券之星 · 09-01
股市必读:同和药业中报 - 第二季度单季净利润同比增长45.08%
同和药业(300636)6月30日股东户数1.59万户,较上期减少2.06%
证券之星 · 08-29
同和药业(300636)6月30日股东户数1.59万户,较上期减少2.06%
8月29日同和药业涨8.25%,湘财医药健康混合A基金重仓该股
证券之星 · 08-29
8月29日同和药业涨8.25%,湘财医药健康混合A基金重仓该股
A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。
金融界 · 08-29
A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。
图解同和药业中报:第二季度单季净利润同比增长45.08%
证券之星 · 08-29
图解同和药业中报:第二季度单季净利润同比增长45.08%
同和药业收盘上涨1.79%,滚动市盈率42.85倍,总市值35.91亿元
金融界 · 08-19
同和药业收盘上涨1.79%,滚动市盈率42.85倍,总市值35.91亿元
同和药业:二厂区二期工程进展顺利
证券之星 · 08-15
同和药业:二厂区二期工程进展顺利
同和药业最新公告:公司原料药美阿沙坦钾通过药品GMP符合性检查
证券之星 · 08-14
同和药业最新公告:公司原料药美阿沙坦钾通过药品GMP符合性检查
同和药业:股东查询股东人数需携带身份证原件及持股证明材料到公司现场
证券之星 · 08-13
同和药业:股东查询股东人数需携带身份证原件及持股证明材料到公司现场
同和药业:6月30日股东人数将会在中报披露
证券之星 · 08-08
同和药业:6月30日股东人数将会在中报披露
同和药业:杭州渤雅专注于长效复杂制剂研发
证券之星 · 08-05
同和药业:杭州渤雅专注于长效复杂制剂研发
同和药业最新公告:公司阿戈美拉汀、奥吡卡朋原料药获得韩国市场准入资格
证券之星 · 07-22
同和药业最新公告:公司阿戈美拉汀、奥吡卡朋原料药获得韩国市场准入资格
暂无数据
公司概况
公司名称:
江西同和药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-03-31
主营业务:
江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。公司的主要产品是特色化学原料药及中间体、专利原料药及中间体。公司是技术驱动型企业,近三年研发投入平均占销售额的比例为8.34%,多次被认定为高新技术企业,先后获批组建了“江西省特色原料药工程技术研究中心”、“博士后科研工作站”、“江西省企业技术中心”、“江西省博士后创新实践基地”、“江西省新药研发产教融合创新中心”等技术创新平台,具有强大的研发能力和技术创新能力。
发行价格:
14.47
{"stockData":{"symbol":"300636","market":"SZ","secType":"STK","nameCN":"同和药业","latestPrice":7.82,"timestamp":1766119449000,"preClose":7.74,"halted":0,"volume":1686968,"delay":0,"changeRate":0.0103,"floatShares":367000000,"shares":420000000,"eps":0.2251,"marketStatus":"午间休市","change":0.08,"latestTime":"12-19 11:30:00","open":7.73,"high":7.85,"low":7.73,"amount":13169800,"amplitude":0.0155,"askPrice":7.83,"askSize":9,"bidPrice":7.82,"bidSize":206,"shortable":0,"etf":0,"ttmEps":0.2251,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766120400000},"marketStatusCode":3,"adr":0,"adjPreClose":7.74,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":8.51,"lowLimit":6.97,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":419951495,"isCdr":false,"pbRate":1.37,"roa":"--","peRate":34.740116,"roe":"3.56%","epsLYR":0.2538,"committee":-0.360123,"marketValue":3284000000,"turnoverRate":0.0046,"status":0,"floatMarketCap":2873000000},"requestUrl":"/m/hq/s/300636/tweets","defaultTab":"tweets","newsList":[{"id":"2589576897","title":"同和药业:公司仅在定期报告中披露截至报告期末的股东人数","url":"https://stock-news.laohu8.com/highlight/detail?id=2589576897","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589576897?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:04","pubTimestamp":1764936240,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月5日,同和药业在互动平台回答投资者提问时表示,为保证所有投资者平等获悉公司信息,公司仅在各定期报告中披露截至报告期末的股东人数情况。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-05/doc-infzuert9398534.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-05/doc-infzuert9398534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2588423087","title":"同和药业:新产能扩建已有潜在客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588423087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588423087?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:18","pubTimestamp":1764659905,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业(300636)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问:周总,请问下公司新产能扩建是否是已有潜在客户,或者已取得客户合作的前提下开展的?谢谢同和药业回复:对的。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2582210153","title":"同和药业(300636)披露2025年第一次临时股东大会决议公告,11月12日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582210153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582210153?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:35","pubTimestamp":1762940140,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘,同和药业报收于8.48元,较前一交易日上涨0.36%,最新总市值为35.61亿元。近日,江西同和药业股份有限公司发布2025年第一次临时股东大会决议公告。公告显示,公司于2025年11月11日召开2025年第一次临时股东大会,审议通过了《关于修订<公司章程>的议案》及多项制度修订与制定议案,包括股东会议事规则、董事会议事规则、独立董事制度等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200028802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2580626792","title":"同和药业(300636.SZ)通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2580626792","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580626792?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:51","pubTimestamp":1762159868,"startTime":"0","endTime":"0","summary":"智通财经APP讯,同和药业(300636.SZ)公告,公司于2025年8月4日至2025年8月7日接受了美国食品药品监督管理局(“美国FDA”)的cGMP(现行药品生产质量管理规范)现场检查,检查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室控制六大系统。近日,公司从美国FDA官网获悉公司已通过了上述现场检查,符合美国FDA的cGMP管理规范。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2578657993","title":"股市必读:同和药业(300636)股东户数1.55万户,较上期减少3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578657993","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578657993?lang=zh_cn&edition=full","pubTime":"2025-10-27 04:50","pubTimestamp":1761511816,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,同和药业报收于8.8元,上涨1.62%,换手率3.28%,成交量12.05万手,成交额1.06亿元。来自公司公告汇总:同和药业将于2025年11月11日召开第一次临时股东大会,审议《关于修订<公司章程>的议案》等多项制度修订事项。股本股东变化股东户数变动截至2025年9月30日,公司股东户数为1.55万户,较6月30日减少482.0户,减幅为3.02%。表决结果均为3票同意,0票反对,0票弃权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2577517098","title":"同和药业(300636)披露召开2025年第一次临时股东大会通知,10月24日股价上涨1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577517098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577517098?lang=zh_cn&edition=full","pubTime":"2025-10-24 22:27","pubTimestamp":1761316043,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,同和药业报收于8.8元,较前一交易日上涨1.62%,最新总市值为36.96亿元。该股当日开盘8.61元,最高8.93元,最低8.57元,成交额达1.06亿元,换手率为3.28%。公司近日发布公告称,江西同和药业股份有限公司将于2025年11月11日召开2025年第一次临时股东大会,会议由公司董事会召集,现场会议时间为当日15:00,网络投票时间为9:15至15:00。股权登记日为2025年11月5日。参会人员食宿及交通费用自理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400042910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2567508108","title":"同和药业(300636.SZ)获得欧洲药典适应性证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2567508108","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567508108?lang=zh_cn&edition=full","pubTime":"2025-09-16 16:54","pubTimestamp":1758012873,"startTime":"0","endTime":"0","summary":"智通财经APP讯,同和药业(300636.SZ)公告,公司近日收到欧洲药品质量管理局(EDQM)颁发的变更后的替格瑞洛原料药欧洲药典适应性证书(CEP),本次变更主要原因为公司新增生产车间,认证范围为:替格瑞洛原料药,变更后的证书自2025年9月12日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2564232108","title":"【机构调研记录】湘财基金调研同和药业、分众传媒等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2564232108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564232108?lang=zh_cn&edition=full","pubTime":"2025-09-02 08:06","pubTimestamp":1756771610,"startTime":"0","endTime":"0","summary":"2)分众传媒 调研纪要:2025年上半年国内广告市场同比上升0.6%,公司实现营收61.12亿元,净利润26.65亿元。已开设近30家国内外运营中心,推动新能源汽车、航空航天等领域整体解决方案落地。制造业恢复带动新能源汽车、航空航天、消费电子等领域刀具需求增长。湘财基金成立于2018年,截至目前,资产管理规模71.35亿元,排名151/210;资产管理规模71.33亿元,排名131/210;管理公募基金数37只,排名115/210;旗下公募基金经理7人,排名126/210。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200006280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0052750758.USD","BK0196","BK0163","LU2008162690.USD","LU2177674079.SGD","002027","BK0098","LU2213484517.USD","BK0210","LU0320764599.SGD","BK0188","300636","LU0708995583.HKD","BK0077","BK0239"],"gpt_icon":0},{"id":"2564868603","title":"股市必读:同和药业中报 - 第二季度单季净利润同比增长45.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564868603","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564868603?lang=zh_cn&edition=full","pubTime":"2025-09-01 07:13","pubTimestamp":1756681994,"startTime":"0","endTime":"0","summary":"来自业绩披露要点:2025年第二季度归母净利润同比增长45.08%,达3770.51万元。股本股东变化股东户数变动截至2025年6月30日,同和药业股东户数为1.59万户,较3月31日减少335.0户,减幅2.06%;户均持股数量由上期的2.59万股上升至2.63万股,户均持股市值为20.23万元。业绩披露要点财务报告同和药业2025年中报显示,公司主营收入4.27亿元,同比上升11.88%;归母净利润5848.65万元,同比下降15.91%;扣非净利润5368.64万元,同比下降20.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100001010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636"],"gpt_icon":0},{"id":"2563404375","title":"同和药业(300636)6月30日股东户数1.59万户,较上期减少2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563404375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563404375?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:37","pubTimestamp":1756460259,"startTime":"0","endTime":"0","summary":"证券之星消息,近日同和药业披露,截至2025年6月30日公司股东户数为1.59万户,较3月31日减少335.0户,减幅为2.06%。在化学制药行业个股中,同和药业股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.29万户。从股价来看,2025年3月31日至2025年6月30日,同和药业区间涨幅为1.73%,在此期间股东户数减少335.0户,减幅为2.06%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900033532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2563538017","title":"8月29日同和药业涨8.25%,湘财医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2563538017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563538017?lang=zh_cn&edition=full","pubTime":"2025-08-29 16:25","pubTimestamp":1756455958,"startTime":"0","endTime":"0","summary":"证券之星消息,8月29日同和药业涨8.25%创60日新高,收盘报8.79元,换手率11.27%,成交量41.38万手,成交额3.71亿元。重仓同和药业的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为湘财基金的湘财医药健康混合A。湘财医药健康混合A目前规模为0.13亿元,最新净值1.6757,较上一交易日下跌0.5%,近一年上涨5.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900029723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2563209143","title":"A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2563209143","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563209143?lang=zh_cn&edition=full","pubTime":"2025-08-29 10:26","pubTimestamp":1756434388,"startTime":"0","endTime":"0","summary":"A股化学制药板块触底反弹,向日葵涨超17%,多瑞医药涨超13%,华海药业、同和药业均涨9%,华纳药厂、立方制药等涨。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/29102652792123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0185","01477","BK0070","BK1191","BK0250","600521","688799","BK0012","003020","159982","300636","399300","BK0156","BK0201","301075","BK0188","300111","BK1574","BK0028","BK0054"],"gpt_icon":0},{"id":"2563504460","title":"图解同和药业中报:第二季度单季净利润同比增长45.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563504460","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563504460?lang=zh_cn&edition=full","pubTime":"2025-08-29 01:48","pubTimestamp":1756403308,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业2025年中报显示,公司主营收入4.27亿元,同比上升11.88%;归母净利润5848.65万元,同比下降15.91%;扣非净利润5368.64万元,同比下降20.5%;其中2025年第二季度,公司单季度主营收入2.41亿元,同比上升36.98%;单季度归母净利润3770.51万元,同比上升45.08%;单季度扣非净利润3600.59万元,同比上升33.16%;负债率28.08%,投资收益-28.08万元,财务费用-1093.81万元,毛利率31.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900000635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636"],"gpt_icon":0},{"id":"2560622341","title":"同和药业收盘上涨1.79%,滚动市盈率42.85倍,总市值35.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2560622341","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560622341?lang=zh_cn&edition=full","pubTime":"2025-08-19 17:40","pubTimestamp":1755596431,"startTime":"0","endTime":"0","summary":"8月19日,同和药业今日收盘8.55元,上涨1.79%,滚动市盈率PE达到42.85倍,总市值35.91亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均65.79倍,行业中值37.53倍,同和药业排名第95位。截至2025年一季报,共有3家机构持仓同和药业,其中基金3家,合计持股数36.06万股,持股市值0.03亿元。江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/19174052537561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2559699965","title":"同和药业:二厂区二期工程进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2559699965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559699965?lang=zh_cn&edition=full","pubTime":"2025-08-15 11:33","pubTimestamp":1755228801,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业08月15日在投资者关系平台上答复投资者关心的问题。投资者提问:同和药业的股价长期低迷,远远的跑输板块,狠狠的伤害了广大投资人的心. 1.请问公司计划如何提振股价和广大股民的投资信心?公司能否尽快提高一厂区和二厂区的产能利用率,大幅度扩广以提高业绩。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500019314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2559195333","title":"同和药业最新公告:公司原料药美阿沙坦钾通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2559195333","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559195333?lang=zh_cn&edition=full","pubTime":"2025-08-14 17:01","pubTimestamp":1755162079,"startTime":"0","endTime":"0","summary":"同和药业(300636.SZ)公告称,公司于近日收到江西省药品监督管理局的药品GMP符合性检查结果告知书,获悉公司本次检查的原料药美阿沙坦钾符合药品GMP。此次检查有利于公司拓展产品在国内市场的销售,形成国内国外市场同步销售的良好格局。但受市场环境等因素影响,具体销售情况存在一定不确定性。公司将按照相关法律法规的要求对后续进展情况履行信息披露义务。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081400031535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2559721126","title":"同和药业:股东查询股东人数需携带身份证原件及持股证明材料到公司现场","url":"https://stock-news.laohu8.com/highlight/detail?id=2559721126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559721126?lang=zh_cn&edition=full","pubTime":"2025-08-13 15:03","pubTimestamp":1755068596,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业08月13日在投资者关系平台上答复投资者关心的问题。中登仅提供特定时点的股东信息,公司无法得知实时的股东人数。股东查阅获悉的股东名册信息应当仅供该股东自身的正当目的使用,不得告知或泄露给其他方。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300018558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2557549608","title":"同和药业:6月30日股东人数将会在中报披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2557549608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557549608?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:03","pubTimestamp":1754640198,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业(300636)08月08日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,公司的股东人数能不能按时定期发布?上次是3月31日的,现在都8月份了,6月31日的股东人数怎么还没发布出来?同和药业回复:感谢您对公司的关注!为保证所有投资者平等获悉公司信息,公司在各定期报告中披露截至报告期末的股东人数情况,6月30日的股东人数将会在中报披露。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800024197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2557368748","title":"同和药业:杭州渤雅专注于长效复杂制剂研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2557368748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557368748?lang=zh_cn&edition=full","pubTime":"2025-08-05 15:06","pubTimestamp":1754377588,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业08月05日在投资者关系平台上答复投资者关心的问题。投资者提问:同和药业其在杭州渤雅的股份为24.9285%,能否介绍一下这家创新药公司的研发团队,在研项目和管线进展情况?同和药业回复:感谢您的关注,本公司参股的杭州渤雅生物医药有限公司2023年成立于杭州,专注于长效复杂制剂的研发和生产,但杭州渤雅并不属于您所说的创新药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500020020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2553652231","title":"同和药业最新公告:公司阿戈美拉汀、奥吡卡朋原料药获得韩国市场准入资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2553652231","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553652231?lang=zh_cn&edition=full","pubTime":"2025-07-22 17:40","pubTimestamp":1753177232,"startTime":"0","endTime":"0","summary":"同和药业(300636.SZ)公告称,公司近日收到韩国食品药品安全部颁发的阿戈美拉汀、奥吡卡朋药品注册证书。这标志着公司阿戈美拉汀、奥吡卡朋原料药获得了韩国市场的准入资格,将对公司进一步扩大国际市场业务起到积极作用。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072200028829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766119496669,"stockEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":-0.0894},{"period":"3month","weight":-0.1234},{"period":"6month","weight":0.0416},{"period":"1year","weight":-0.0648},{"period":"ytd","weight":-0.0237}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江西同和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15461人(较上一季度减少3.02%)","perCapita":"23760股","listingDate":"2017-03-31","address":"江西省宜春市奉新县江西奉新高新技术产业园区","registeredCapital":"41995万元","survey":" 江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。公司的主要产品是特色化学原料药及中间体、专利原料药及中间体。公司是技术驱动型企业,近三年研发投入平均占销售额的比例为8.34%,多次被认定为高新技术企业,先后获批组建了“江西省特色原料药工程技术研究中心”、“博士后科研工作站”、“江西省企业技术中心”、“江西省博士后创新实践基地”、“江西省新药研发产教融合创新中心”等技术创新平台,具有强大的研发能力和技术创新能力。","listedPrice":14.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同和药业,300636,同和药业股票,同和药业股票老虎,同和药业股票老虎国际,同和药业行情,同和药业股票行情,同和药业股价,同和药业股市,同和药业股票价格,同和药业股票交易,同和药业股票购买,同和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}